{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-085474","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.264018+00:00","generated_at":"2026-05-15T22:44:58.714798+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts","bullets":["IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.","Entered exclusive licensing/collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and other regions.","Cash, equivalents, and marketable securities of $529.2M as of Dec 31, 2025.","Net product revenue from IBTROZI: $15.7M in Q4 2025, $24.7M for full year 2025.","Positive Phase 2 safusidenib results published; ORR 44%, 88% progression-free at 24 months in grade 2 IDH1-mutant glioma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-085474","json":"https://secwatch.observer/filing/0001193125-26-085474.json","markdown":"https://secwatch.observer/filing/0001193125-26-085474.md","text":"https://secwatch.observer/filing/0001193125-26-085474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/0001193125-26-085474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/d15383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T22:44:58.714798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}